ArticlePloS one2025
Investigation of phytochemical and biochemical attributes of hypoglycemic activity of Atriplex crassifolia (C.A. Mey) extracts in alloxan diabetic animal model.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a widespread medical and public health issue that can lead to significant health impairment. The objective of the study was to assess the antidiabetic effectiveness of various extracts of Atriplex crassifolia (A. crassifolia), namely n-hexane (ACNH), dichloromethane (ACDCM), ethyl acetate (ACEA), and n-butanol (ACNB). The initial qualitative analysis revealed the presence of bioactive components in all extracts, such as alkaloids, glycosides, phenols, flavonoids, terpenes, and saponins. ACEA and ACNB exhibited considerable radical scavenging activity at different doses, as determined by the DPPH free radical scavenging experiment used to assess in-vitro antioxidant activity. Male rats were administered 150 mg/kg of alloxan monohydrate to develop diabetes. A preliminary investigation was conducted to evaluate the potential of all extracts to lower blood glucose levels using an oral glucose tolerance test (OGTT) at three different doses (250, 500, and 1000 mg/kg/day). ACEA and ACNB exhibited promising results in the OGTT, thus prompting a 28-day hypoglycemic research to confirm their biological effectiveness in treating diabetes. When taken orally, ACEA at doses of 500 and 1000 mg/kg/day, and ACNB at doses of 250, 500, and 1000 mg/kg/day, effectively recovered the concentrations of urea, creatinine, glucose, cholesterol, triglycerides, HDL, and liver enzymes (AST, ALT, and ALP). The histopathological evidence corroborated the conclusions. HPLC and GC-MS were employed to identify the presence of medically important phytoconstituents in ACEA and ACNB. Myrecitin and Quercitin were found using High Performance Liquid Chromatography (HPLC) in ACEA, while sinapic acid was identified in ACNB. The GC-MS analyses of ACEA and ACNB revealed the presence of several compounds with hypolipidemic, antioxidant, and anti-diabetic properties. The present study suggests that A. crassifolia has potential as a natural remedy for managing hyperglycemia, diabetic hyperlipidemia, and other diabetes-related problems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.